Clinical Trials Browser

Interventional × cemiplimab × Clear all

NCT05317858 2026-04-16

LIMITLESS

Phase 3 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06568172 2026-04-16

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Recruiting

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT06980038 2026-04-16

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT07470489 2026-04-16

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

Phase 2 Not yet recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT05704634 2026-04-15

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Phase 1 Active not recruiting

Lung Neoplasms

NCT07020065 2026-04-15

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05142189 2026-04-14

LuCa-MERIT-1

Phase 1 Recruiting

EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT05208944 2026-04-14

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06900595 2026-04-14

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Phase 2 Recruiting

Adrenocortical Carcinoma

NCT06931717 2026-04-14

ARCH

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07527325 2026-04-14

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

Phase 2 Not yet recruiting

Melanoma

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT05553834 2026-04-13

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1 Recruiting

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT06865339 2026-04-13

TRIPL

Phase 2 Recruiting

NSCLC

NCT07147231 2026-04-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07195734 2026-04-13

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Phase 2 Recruiting

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07281417 2026-04-13

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Phase 2 Recruiting

Sinonasal Squamous Cell Carcinoma

NCT07422363 2026-04-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 1 Not yet recruiting

Glioblastoma, Gliosarcoma

NCT04626635 2026-04-09

COMBINE-EGFR-1

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06790602 2026-04-09

SWITCH

Phase 2 Recruiting

Neoplasm Metastasis

NCT06585410 2026-04-08

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Phase 3 Recruiting

Skin Neoplasms

NCT06787612 2026-04-08

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03916627 2026-04-06

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase 2 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT05064085 2026-04-06

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

Phase 2 Not yet recruiting

Melanoma

NCT06162572 2026-04-03

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07188896 2026-04-03

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT04722523 2026-03-30

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 3 FDA

Cutaneous Squamous Cell Carcinoma

NCT05929664 2026-03-24

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Phase 2 Recruiting

Carcinoma, Basal Cell

NCT06651593 2026-03-24

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

NCT06943664 2026-03-24

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT06769698 2026-03-23

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07281768 2026-03-20

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT03491683 2026-03-19

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

Glioblastoma

NCT06205836 2026-03-17

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05401786 2026-03-12

RAD-IO

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06384807 2026-03-11

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06981325 2026-03-11

CEMI-first

Phase 2 Recruiting

Carcinoma, Basal Cell, Skin Neoplasms

NCT06171750 2026-03-06

ANCHOR

Phase 1 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Skin Neoplasms

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06699602 2026-03-04

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT06826768 2026-03-04

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Phase 1 Recruiting

Prostatic Neoplasms

NCT07179315 2026-03-04

A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

Phase 2 Not yet recruiting

Head and Neck Neoplasms

NCT07450183 2026-03-04

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms